SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy - Michelle PhamView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website - Sara GibbonsView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Clinical Case Presentation - Catia Marzolini, PharmD, PhDView Slideset
SlidesetRSVHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Long Acting HIV Drugs for Prevention: Data and Potential implementation - Laura Waters, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Long acting HIV drugs for treatment: Data and potential implementation - Charles Flexner, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Improved long acting drug delivery: What are the technologies - Andrew Owen, BSc, MSc, PhD, FSBView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Novel antiviral and immune targets to cure HBV - Fabien Zoulim, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254 - Samit Joshi, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019In silico design of a microarray patch as a multipurpose prevention technology - Rajith RajoliView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine - Anthony Podany, PharmDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The ‘third wave’ of TB drug development what’s on the horizon (for patients with or without HIV) - Kelly Dooley, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 201950% Adherence is enough with modern ARVS, right - Terrence Blaschke, MDView Slideset
